ESR1 and breast cancer: Thus, Lundberg and coworkers have explored the long-term prognostic and predictive capacity of cyclin D1 gene amplification in 2305 breast cancers, showing that a worse survival was observed for patients with luminal A and luminal B, ER+, lymph node-negative, HER2- breast cancers [341].